Dermatology · Bowling Green, KY
Dermatology and skin studies in Bowling Green, KY
11 recruiting studies have a site in Bowling Green.
11 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Bowling Green, KY + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Apogee Therapeutics, Inc.
- Location
- Bowling Green, KY + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
- Location
- Bowling Green, KY + 18 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Spyre Therapeutics, Inc.
- Location
- Bowling Green, KY + 6 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc.
- Location
- Bowling Green, KY + 8 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Bowling Green, KY + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 1
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Incyte Corporation
- Location
- Bowling Green, KY + 15 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- Bowling Green, KY + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU…
Celldex Therapeutics
- Location
- Bowling Green, KY + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Bowling Green, KY + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Sanofi Pasteur, a Sanofi Company
- Location
- Bowling Green, KY + 78 other US sites
- Eligibility basics
- Ages 18–45
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.